New drug trial offers hope for kidney disease patients

NCT ID NCT07522099

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 14, 2026 · Last updated May 22, 2026 · Updated 7 times

Summary

This study tests a new drug called ADX-038 in 30 Chinese adults with kidney diseases caused by the immune system attacking the kidneys. The goal is to see if the drug is safe and can help control the disease. Some participants will get ADX-038 alone, and others will get it with another drug called telitacicept.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ADARx Clinical Site
RECRUITING

Shenzhen, Guangdong, 518100, China
ADARx Clinical Site
RECRUITING

Guiyang, Guizhou, China
ADARx Clinical Site
NOT_YET_RECRUITING

Zhengzhou, Henan, China
ADARx Clinical Site
RECRUITING

Baotou, Inner Mongolia, 014000, China
ADARx Clinical Site
RECRUITING

Wuxi, Jiangsu, 214000, China
ADARx Clinical Site
RECRUITING

Yantai, Shandong, 264008, China
ADARx Clinical Site
RECRUITING

Beijing, 100034, China
ADARx Clinical Site
NOT_YET_RECRUITING

Shandong, China
ADARx Clinical Site
NOT_YET_RECRUITING

Shanghai, China
ADARx Clinical Site
NOT_YET_RECRUITING

Shangxi, China

Conditions

Explore the condition pages connected to this study.

COMPLEMENT 3 GLOMERULOPATHY (C3G) IC-MPGN IC-MPGN IMMUNOGLOBULIN A NEPHROPATHY (IGAN)